149 related articles for article (PubMed ID: 8809640)
41. Use of decision analysis to evaluate the costs and benefits of filgrastim (G-CSF) therapy.
Peroutka JA; Mutnick AH
Formulary; 1995 Jul; 30(7):394-5, 400-4. PubMed ID: 10151731
[TBL] [Abstract][Full Text] [Related]
42. [Problems and recommendations for use of G-CSF in lung cancer patients with neutropenia after chemotherapy].
Ogawara M
Gan To Kagaku Ryoho; 1997 Oct; 24 Suppl 3():439-44. PubMed ID: 9369920
[TBL] [Abstract][Full Text] [Related]
43. Neutropenic complications in advanced-stage non-Hodgkin's lymphoma: implications for the use of prophylactic recombinant human granulocyte-colony stimulating factor (G-CSF).
Bobey N; Woodman RC
Clin Invest Med; 1998 Apr; 21(2):63-70. PubMed ID: 9562926
[TBL] [Abstract][Full Text] [Related]
44. A Randomized Multicenter Phase III Study of Single Administration of Mecapegfilgrastim (HHPG-19K), a Pegfilgrastim Biosimilar, for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients With Advanced Non-Small-Cell Lung Cancer (NSCLC).
Zhou C; Huang Y; Wang D; An C; Zhou F; Li Y; Chen G; Wu C; He J; Wu G; Song X; Gao J; Liu W; Li B; Shi J; Huang C; Yu J; Feng J; Yue H; Shi M; Xia J
Clin Lung Cancer; 2016 Mar; 17(2):119-27. PubMed ID: 26781346
[TBL] [Abstract][Full Text] [Related]
45. [Prevention and treatment of febrile neutropenia].
Montemurro F; Gallicchio M; Aglietta M
Tumori; 1997; 83(2 Suppl):S15-9. PubMed ID: 9235724
[TBL] [Abstract][Full Text] [Related]
46. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
Nabholtz JM; Cantin J; Chang J; Guevin R; Patel R; Tkaczuk K; Vodvarka P; Lindsay MA; Reese D; Riva A; Mackey J
Clin Breast Cancer; 2002 Oct; 3(4):268-75. PubMed ID: 12425755
[TBL] [Abstract][Full Text] [Related]
47. Cost analyses of granulocyte colony stimulating factor: a focus on older patients with cancer.
Bennett CL
Crit Rev Oncol Hematol; 2003 Oct; 48(Suppl):S71-4. PubMed ID: 14563524
[TBL] [Abstract][Full Text] [Related]
48. XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy.
Gatzemeier U; Ciuleanu T; Dediu M; Ganea-Motan E; Lubenau H; Del Giglio A
J Thorac Oncol; 2009 Jun; 4(6):736-40. PubMed ID: 19404210
[TBL] [Abstract][Full Text] [Related]
49. [A multicenter, randomized, controlled, phase Ⅲ clinical study of PEG-rhG-CSF for preventing chemotherapy-induced neutropenia in patients with breast cancer and non-small cell lung cancer].
Xu B; Tian F; Yu J; Song Y; Shi J; Zhang B; Zhang Y; Yuan Z; Wu Q; Zhang Q; Nan K; Sun Q; Li W; Hu J; Bi J; Meng C; Dai H; Jiang H; Yue S; Cao B; Sun Y; Wang S; Tong Z; Shen P; Wu G; Tang L; Deng Y; Jia L; Shen K; Zhuang W; Xie X; Wu Y; Chen L
Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):23-7. PubMed ID: 26796802
[TBL] [Abstract][Full Text] [Related]
50. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial.
Schiller JH; Kim K; Hutson P; DeVore R; Glick J; Stewart J; Johnson D
J Clin Oncol; 1996 Aug; 14(8):2345-52. PubMed ID: 8708727
[TBL] [Abstract][Full Text] [Related]
51. Pharmacoeconomics of the myeloid growth factors: a critical and systematic review.
Hirsch BR; Lyman GH
Pharmacoeconomics; 2012 Jun; 30(6):497-511. PubMed ID: 22540394
[TBL] [Abstract][Full Text] [Related]
52. Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients.
Lathia N; Isogai PK; De Angelis C; Smith TJ; Cheung M; Mittmann N; Hoch JS; Walker S
J Natl Cancer Inst; 2013 Aug; 105(15):1078-85. PubMed ID: 23873405
[TBL] [Abstract][Full Text] [Related]
53. Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia.
Aarts MJ; Grutters JP; Peters FP; Mandigers CM; Dercksen MW; Stouthard JM; Nortier HJ; van Laarhoven HW; van Warmerdam LJ; van de Wouw AJ; Jacobs EM; Mattijssen V; van der Rijt CC; Smilde TJ; van der Velden AW; Temizkan M; Batman E; Muller EW; van Gastel SM; Joore MA; Borm GF; Tjan-Heijnen VC
J Clin Oncol; 2013 Dec; 31(34):4283-9. PubMed ID: 24166522
[TBL] [Abstract][Full Text] [Related]
54. Comparative effectiveness of pegfilgrastim, filgrastim, and sargramostim prophylaxis for neutropenia-related hospitalization: two US retrospective claims analyses.
Henk HJ; Becker L; Tan H; Yu J; Kavati A; Naeim A; Deeter R; Barron R
J Med Econ; 2013; 16(1):160-8. PubMed ID: 23016568
[TBL] [Abstract][Full Text] [Related]
55. Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer.
Woll PJ; Hodgetts J; Lomax L; Bildet F; Cour-Chabernaud V; Thatcher N
J Clin Oncol; 1995 Mar; 13(3):652-9. PubMed ID: 7533825
[TBL] [Abstract][Full Text] [Related]
56. Cost analysis of filgrastim for the prevention of neutropenia in pediatric T-cell leukemia and advanced lymphoblastic lymphoma: a case for prospective economic analysis in cooperative group trials.
Bennett CL; Stinson TJ; Lane D; Amylon M; Land VJ; Laver JH
Med Pediatr Oncol; 2000 Feb; 34(2):92-6. PubMed ID: 10657867
[TBL] [Abstract][Full Text] [Related]
57. A retrospective study of patients' out-of-pocket costs for granulocyte colony-stimulating factors.
Tomic K; Long S; Li X; Fu AC; Yu TC; Barron R
J Oncol Pharm Pract; 2013 Dec; 19(4):328-37. PubMed ID: 23353712
[TBL] [Abstract][Full Text] [Related]
58. Review of granulocyte colony-stimulating factors in the treatment of established febrile neutropenia.
Pérez Velasco R
J Oncol Pharm Pract; 2011 Sep; 17(3):225-32. PubMed ID: 20562168
[TBL] [Abstract][Full Text] [Related]
59. Routine use of granulocyte colony-stimulating factor is not cost-effective and does not increase patient comfort in the treatment of small-cell lung cancer: an analysis using a Markov model.
Chouaid C; Bassinet L; Fuhrman C; Monnet I; Housset B
J Clin Oncol; 1998 Aug; 16(8):2700-7. PubMed ID: 9704720
[TBL] [Abstract][Full Text] [Related]
60. Pegfilgrastim: a review of the pharmacoeconomics for chemotherapy-induced neutropenia.
Rofail P; Tadros M; Ywakim R; Tadrous M; Krug A; Cosler LE
Expert Rev Pharmacoecon Outcomes Res; 2012 Dec; 12(6):699-709. PubMed ID: 23252353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
